MML Investors Services
TAK icon

MML Investors Services’s Takeda Pharmaceutical TAK Stock Holding History

MML Investors Services’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
96,887
+19,422
+25% +$321K ﹤0.01% 1716
2026
Q1 		$1.43M Sell
77,465
-24,379
-24% -$428K ﹤0.01% 1522
2025
Q4 		$1.59M Buy
101,844
+12,216
+14% +$175K ﹤0.01% 1515
2025
Q3 		$1.31M Buy
89,628
+8,799
+11% +$131K ﹤0.01% 1547
2025
Q2 		$1.25M Buy
80,829
+11,543
+17% +$171K ﹤0.01% 1531
2025
Q1 		$1.03M Buy
69,286
+7,133
+11% +$99.9K ﹤0.01% 1550
2024
Q4 		$823K Buy
62,153
+21,055
+51% +$289K ﹤0.01% 1633
2024
Q3 		$584K Buy
41,098
+4,485
+12% +$63.6K ﹤0.01% 1770
2024
Q2 		$474K Sell
36,613
-7,288
-17% -$96.5K ﹤0.01% 1822
2024
Q1 		$610K Sell
43,901
-91
-0.2% -$1.32K ﹤0.01% 1690
2023
Q4 		$628K Buy
43,992
+5,229
+13% +$74.2K ﹤0.01% 1623
2023
Q3 		$600K Buy
38,763
+11,053
+40% +$171K ﹤0.01% 1514
2023
Q2 		$435K Buy
27,710
+7,998
+41% +$131K ﹤0.01% 1721
2023
Q1 		$325K Sell
19,712
-8,130
-29% -$130K ﹤0.01% 1632
2022
Q4 		$434K Buy
27,842
+3,338
+14% +$46.6K ﹤0.01% 1575
2022
Q3 		$318K Buy
24,504
+3,008
+14% +$41.8K ﹤0.01% 1648
2022
Q2 		$302K Buy
21,496
+627
+3% +$8.95K ﹤0.01% 1683
2022
Q1 		$299K Buy
20,869
+998
+5% +$14.7K ﹤0.01% 1731
2021
Q4 		$271K Sell
19,871
-4,134
-17% -$58K ﹤0.01% 1755
2021
Q3 		$393K Buy
24,005
+142
+0.6% +$2.38K ﹤0.01% 1485
2021
Q2 		$402K Sell
23,863
-13,536
-36% -$230K ﹤0.01% 1443
2021
Q1 		$683K Buy
37,399
+4,404
+13% +$79.2K 0.01% 1101
2020
Q4 		$601K Buy
32,995
+4,453
+16% +$78.1K 0.01% 1064
2020
Q3 		$509K Buy
28,542
+1,560
+6% +$28.4K 0.01% 1035
2020
Q2 		$484K Sell
26,982
-1,092
-4% -$19.6K 0.01% 1009
2020
Q1 		$426K Buy
28,074
+9,284
+49% +$168K 0.01% 944
2019
Q4 		$371K Buy
18,790
+2,448
+15% +$46.8K 0.01% 1129
2019
Q3 		$281K Buy
16,342
+1,995
+14% +$34.5K ﹤0.01% 1221
2019
Q2 		$254K Buy
14,347
+2,781
+24% +$50.6K ﹤0.01% 1383
2019
Q1 		$236K Buy
+11,566
New +$233K ﹤0.01% 1395

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

MML Investors Services's TAK Position: Q2 2026 in Review

MML Investors Services increased its Takeda Pharmaceutical (TAK) stake by 25% in Q2 2026, buying an estimated $321K and bringing the position to 96,887 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

MML Investors Services first reported a position in TAK in Q1 2019 and has held it in 30 quarters since. The position peaked at $1.59M in Q4 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • MML Investors Services held 96,887 shares of Takeda Pharmaceutical worth $1.55M as of Q2 2026.
  • MML Investors Services bought 19,422 Takeda Pharmaceutical shares in Q2 2026, an estimated $321K.
  • Takeda Pharmaceutical made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #1716 holding.
  • MML Investors Services first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 30 quarters since.
  • MML Investors Services's Takeda Pharmaceutical position peaked at $1.59M in Q4 2025.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.